Rhythm Pharmaceuticals (RYTM) Misses Q2 EPS by 8c

Rhythm Pharmaceuticals (NASDAQ: RYTM) reported Q2 EPS of ($0.75), $0.08 worse than the analyst estimate of ($0.67).

For earnings history and earnings-related data on Rhythm Pharmaceuticals (RYTM) click here.

You May Also Be Interested In

• Rubico to shift from semi-annual to quarterly financial reporting
• Vivmark Residential (VMRK) Reiterated at Buy by Stifel on >95% Physical Occupancy
• HeartBeam shifts focus to heart attack detection, away from arrhythmia